Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology firm, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 11:30 am ET. The discussion will address their innovative therapeutic approaches combining targeted and immune-mediated mechanisms for cancer treatment. Key programs include TPST-1120 and TPST-1495, which are in clinical trials aimed at enhancing cancer therapies. Interested parties can access the live or archived chat via the investor section of Tempest's website.

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:30 am ET.

To access the live or archived recording of the chat, please visit the investor section of the Tempest website at https://ir.tempesttx.com.

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both tumor-targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1120 and TPST-1495, antagonists of PPARα and EP2/EP4, respectively. Both programs are advancing through clinical trials designed to study the agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX1, a target that controls activation of the cGAS/STING pathway. Tempest is headquartered in South San Francisco. More information about Tempest can be found on the company’s website at www.tempesttx.com.

Investor Contacts:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

When will Tempest Therapeutics participate in the Piper Sandler Healthcare Conference?

Tempest Therapeutics will participate in the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 11:30 am ET.

What are the key clinical programs of Tempest Therapeutics?

Tempest Therapeutics is advancing two key programs: TPST-1120 and TPST-1495, both of which are in clinical trials targeting cancer.

How can I access the fireside chat for Tempest Therapeutics?

You can access the live or archived recording of the fireside chat by visiting the investor section of Tempest's website.

What is the focus of Tempest Therapeutics in oncology?

Tempest Therapeutics focuses on developing first-in-class therapeutics that combine targeted and immune-mediated mechanisms to treat a range of tumors.

What is the stock symbol for Tempest Therapeutics?

The stock symbol for Tempest Therapeutics is TPST.